CAF interacts with specific genetic variants such as MAPT, SLC2A13, LRRK2, ApoE, NOS2A, GRIN2A, CYP1A2, and ADORA2A, which may influence the risk of developing Parkinson’s Disease (PD). This evidence concerns the gene MAPT and Parkinson disease.